Portfolio Intelligence System
Biotica Bio helps investors, founders, and BD teams turn complex science into structured commercial judgment: where an asset fits, which opportunities matter, and what to do next.
One-line promise
A repeatable way to map, score, and rank biotech opportunities so you can decide faster—with evidence you can trace.
Illustrative deliverable (same biology as other offers)
Product framing (illustrative): A proposed IaIP blood product (plasma-derived or recombinant protein therapeutic), with mechanistic story anchored on ITIH / inter-alpha-trypsin inhibitor biology in Open Targets.
| Deliverable | Open Targets (example pulls) | Orange Book (example pulls) |
|---|---|---|
| Opportunity Map | ITIH targets linked to candidate indications; genetics / associations; known drugs and clinical candidates on adjacent mechanisms and biologic density in those indications—not “IaIP” as if it were one OT drug record. | Listed products relevant to injectable / systemic protein precedent and ingredient-level rows where OB is the right source; explicit note when BLA-class blood products are under-represented in OB so differentiation is not read off an empty search. |
| Executive rendering | IC-ready: what OT does and does not imply for indication choice for a blood product. | IC-ready: where listed comparators support a crowding story vs where precedent lives outside OB. |
This is one vignette to show artifact shape; full three-offer thread · Contact for your entities.
Who it is for
- Venture, crossover, and strategic healthcare investors
- CEOs and heads of BD evaluating assets, indications, or partnerships
- Portfolio teams triaging multiple programs
What problem it solves
Science-based companies face information asymmetry: public data exists, but turning it into comparable, decision-ready intelligence is slow and error-prone. This offer delivers a named method and a durable structured artifact, not a one-off narrative.
The method: Biotica Opportunity Mapping Method
- Decision framing — One explicit question (e.g. indication choice, partner list, whitespace map).
- Entity normalization — Canonical map of targets, diseases, drugs, comparators, and partner candidates.
- Evidence layer assembly — Biology, indication landscape, competitive density, modality precedent, and (when scoped) trials, payer, or structure-informed layers.
- Opportunity scoring — Transparent criteria and ranked options.
- Decision rendering — Executive brief, IC appendix, partner list, or portfolio memo—consistent with the same underlying map.
The artifact: Biotica Opportunity Map
The core output is a structured opportunity map: normalized entities, evidence dimensions, optional score rows, recommendations, and provenance. Narrative reports are one rendering of that object.
API-backed report runs that complete successfully also emit opportunity-map.json alongside report.md for the same run.
Evidence and tools
Portfolio Intelligence is not “an Open Targets report” as the brand—it is decision-ready mapping and synthesis. Public evidence layers are chosen to match the question:
| Layer | Role |
|---|---|
| Open Targets Platform | Integrated graph of targets, diseases, drugs, associations, tractability, safety, and more—our default biology and landscape backbone when scoped. Deep dive: The platform. |
| FDA Orange Book | Approved-drug precedent: listed comparators, differentiation vs crowding—not a prediction your asset will be approved. Used when commercial and BD questions need “what is already on the market?” |
| Trials / policy / CMS (when scoped) | Context for development and access narratives when your question requires it. |
| Structure-informed (optional) | Computational structural hypotheses (e.g. AlphaFold-class) alongside OT ± OB—Structure-informed diligence module. |
Reproducibility and query flow: How it’s built.
What you receive
- Opportunity Map (structured) plus executive brief or memo as agreed in scope
- Cross-layer synthesis when you need Open Targets, Orange Book precedent, and optional structure-informed reads in one package — see Structure-informed diligence (Offer 1 module)
Next step
Contact with your decision question and entities. Review How it’s built for reproducible evidence workflow.
Outputs are for strategic and due-diligence use only; they do not constitute regulatory, medical, or investment advice.